Pharmaceutical Industry Blog

Last Updated: July 26, 2026 TL;DR: Burkina Faso is a landlocked West African market of about 24.1 million people that imports more than 90% of the medicines it consumes and has no domestic sterile injectable capacity. India is already its second-largest source of packaged medicines. The regulator is the Agence Nationale de Régulation Pharmaceutique (ANRP), created in October 2018 and ISO 9001:2015 certified; it grants a five-year Autorisation de Mise sur le Marché under UEMOA

Last Updated: July 26, 2026 TL;DR: Mali is a landlocked Sahelian market of about 25.2 million people carrying one of the heaviest injectable-medicine burdens in the world, with effectively no domestic sterile manufacturing capacity to meet it. The regulator is the Direction de la Pharmacie et du Médicament (DPM) inside the Ministry of Health, not a standalone agency, and the Autorisation de Mise sur le Marché (AMM) it grants is valid for five years. Dossiers follow the UEMOA

Last Updated: July 25, 2026 TL;DR: Syria is the most changed pharmaceutical market in the Middle East. Since the transition of December 2024 the United States has terminated its Syria sanctions programme by Executive Order 14312 with effect from 1 July 2025, removed the Syrian Sanctions Regulations from the Code of Federal Regulations in August 2025 and repealed the Caesar Act outright on 18 December 2025; the European Union lifted all economic sanctions on 28 May 2025 and re

Last Updated: July 25, 2026 TL;DR: Niger is a Sahelian market of roughly 28 million people with one of the heaviest injectable-medicine burdens in the world and almost no domestic capacity to fill it. It is a WHO High Burden to High Impact malaria country — an estimated 7,982,516 cases and 35,381 deaths in 2023, about 3% of global malaria cases and 5.9% of global malaria deaths — and its own national guidelines make intravenous artesunate or artemether the first-line treatmen

Last Updated: July 24, 2026 TL;DR: Venezuela is a market of roughly 28 to 29 million residents — after an emigration of some 7.7 million people — where a prolonged humanitarian and economic crisis has hollowed out both public procurement and domestic manufacturing, leaving deep, genuine demand for affordable sterile injectables. Local production fell by around 70% over the crisis and the industry now depends on imports for roughly 98% of its inputs; medicine shortages reached

Last Updated: July 24, 2026 TL;DR: Cameroon is a market of roughly 30 to 31 million people that imports the overwhelming majority of the medicines it consumes — local production covers only about 5% and there is no domestic maker of small-volume sterile injectables. Demand is heavy: Cameroon is one of the world’s eleven High Burden to High Impact malaria countries, with an estimated 7.6 million cases and around 11,700 deaths in 2024; cancer already accounts for roughly 19,600